# Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC

> **NCT07733830** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Nab paclitaxel
- **DRUG:** Carboplatin
- **RADIATION:** radiation

## Key facts

- **NCT ID:** NCT07733830
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733830, "Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*